StockDriftsStockDriftsGenome & Company (314130) has 0 disclosed insider purchases and 2 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩155M ($107K) in reported transaction value. The earliest filing StockDrifts holds for Genome & Company is dated 2024-08-07; the most recent is 2026-05-21. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +0.72%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | SELL | 증여 | 박한수 Park Hansu | Each CEO | -20.0K | ₩5,200 | -6.7% | ₩104M ($72K) |
| 2026-05-21 | BUY | 수증 | 차미영 Cha Mi-young | vice president | 20.0K | ₩5,200 | +6.7% | ₩104M ($72K) |
| 2026-04-23 | BUY | 주식매수청구권 행사 | 서진경 Seo Jin-kyung | Managing Director | 26.0K | ₩6,100 | +15.7% | ₩159M ($110K) |
| 2026-03-27 | SELL | Market Sell | 유현경 Hyeonkyung Yoo | Managing Director | -6.0K | ₩9,580 | +0.0% | ₩57M ($40K) |
| 2026-03-26 | SELL | Market Sell | 서진경 Seo Jin-kyung | Managing Director | -10.0K | ₩9,720 | +1.4% | ₩97M ($68K) |
| 2025-04-30 | SELL | 증여 | 배지수 badge number | Each CEO | -90.0K | ₩2,780 | -171.9% | ₩250M ($174K) |
| 2025-04-30 | BUY | 수증 | 박병규 Park Byeong-gyu | Managing Director | 50.0K | ₩2,780 | +171.9% | ₩139M ($97K) |
| 2025-04-30 | BUY | 수증 | 차미영 Cha Mi-young | Managing Director | 20.0K | ₩2,780 | +171.9% | ₩56M ($39K) |
| 2025-04-30 | BUY | 수증 | 김상균 Kim Sang-gyun | Managing Director | 40.0K | ₩2,780 | +171.9% | ₩111M ($77K) |
| 2025-04-30 | BUY | 수증 | 유현경 Hyeonkyung Yoo | Managing Director | 20.0K | ₩2,780 | +171.9% | ₩56M ($39K) |
| 2025-04-30 | SELL | 증여 | 박한수 Park Hansu | Each CEO | -100.0K | ₩2,780 | -171.9% | ₩278M ($193K) |
| 2025-04-30 | BUY | 수증 | 서진경 Seo Jin-kyung | Managing Director | 10.0K | ₩2,780 | +171.9% | ₩28M ($19K) |
| 2024-12-06 | BUY | 기타 | 차미영 Cha Mi-young | Managing Director | 12.0K | ₩2,660 | +184.2% | ₩32M ($22K) |
| 2024-08-07 | BUY | 무상신주취득 | 홍유석 Hong Yu-seok | General representative | 5.0K | ₩5,160 | +46.5% | ₩26M ($18K) |
| 2024-08-07 | BUY | 무상신주취득 | 배지수 badge number | Each CEO | 1.6M | ₩5,160 | +46.5% | ₩8.1B ($5.6M) |
| 2024-08-07 | BUY | 무상신주취득 | 김상균 Kim Sang-gyun | Managing Director | 7.5K | ₩5,160 | +46.5% | ₩39M ($27K) |
| 2024-08-07 | BUY | 무상신주취득 | 박한수 Park Hansu | Each CEO | 1.7M | ₩5,160 | +46.5% | ₩8.8B ($6.1M) |
Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Genome & Company. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.